Vidaza

Phase 1Small molecule

Bristol-Myers Squibb

Vidaza is one of 173 small molecule programs targeting Myelodysplastic Syndrome. It is currently in Phase 1.

Indications

Total Trials

Active Trials

172

Competitors

Pipeline

Status by Indication[3][1]

Indication

Myelodysplastic SyndromeActive, not recruiting

Non-Small Cell Lung CancerActive, not recruiting

Pancreatic CancerActive, not recruiting

Acute Myeloid LeukemiaActive, not recruiting

Myelodysplastic SyndromesActive, not recruiting

Myelodysplastic SyndromePhase 1

Active, not recruiting

Non-Small Cell Lung CancerPreclinical

Active, not recruiting

Pancreatic CancerPhase 1

Active, not recruiting

Acute Myeloid LeukemiaPhase 1/Phase 2

Active, not recruiting

Myelodysplastic SyndromesPhase 1

Active, not recruiting

Competition

Competitive Landscape

1639 competitors in Non-Small Cell Lung Cancer

#DrugCompanyPhaseTrials

Yervoy

Bristol-Myers Squibb

Preclinical

31 2

Gemzar

GGynecologic Oncology Group

Preclinical

72 3

Vizimpro

Pfizer

Preclinical

4 4

Gilotrif

Boehringer Ingelheim

Preclinical

12 5

Immunotherapy

Bristol-Myers Squibb

Preclinical

12 6

Vidaza

Bristol-Myers Squibb

Phase 1

1 7

Remeron

OOrganon and Co

Preclinical

1 8

Tyrosine Kinase Inhibitor

Pfizer

Preclinical

2 9

Treatment

GSK

Preclinical

1 10

Immune Checkpoint Inhibitor

IImmuneSensor Therapeutics Inc.

Preclinical

Ranked by pipeline maturity and clinical activity. Current drug highlighted in teal.

Clinical

Trials by Indication[1]

Myelodysplastic Syndrome2 trials

Phase 1 Study to Evaluate MEDI4736 in Subjects With Myelodysplastic Syndrome

Completed· AstraZeneca logo

AstraZeneca·Phase 1·NCT02117219·67 enrolled

Bioequivalence Study of Azacitidine for Injection in Myelodysplastic Syndrome (MDS) Patients

Completed·BBioniche Pharma USA LLC·Phase 1·NCT01152346·19 enrolled

Non-Small Cell Lung Cancer1 trial

Residual Hypermethylation in Early Stage Non-Small Cell Lung Cancer (NSCLC) As Part of Adjuvant Therapy and Preventive Strategy

Completed·UUniversity of Miami·N/A·NCT01209520·6 enrolled

Safety and Efficacy1 trial

Post Marketing Surveillance to Collect and Evaluate the Safety and Efficacy Information of Korean MDS Patients Treated With VIDAZA®, After Approval of Marketing Authorization for New Drug in Korea

Completed· Bristol-Myers Squibb logo

Bristol-Myers Squibb··NCT02137629·511 enrolled

Hematologic Malignancies1 trial

Bioequivalence & Food Effect Study in Patients With Solid Tumor or Hematologic Malignancies

Completed· Bristol-Myers Squibb logo

Bristol-Myers Squibb·Phase 1·NCT02223052·89 enrolled

Acute Myeloid Leukemia1 trial

A Study Assessing tOTX015 in Combination With Azacitidine (AZA) or AZA Single Agent in Patients With Newly-diagnosed Acute Myeloid Leukemia (AML) Not Candidate for Standard Intensive Induction Therapy (SIIT)

Withdrawn· Merck & Co. logo

Merck & Co.·Phase 1/2·NCT02303782

3 more indications

Pancreatic Cancer1 trial

Phase I Trial of 5-Azacitidine Plus Gemcitabine in Patients With Advanced Pancreatic Cancer

Terminated·UUniversity of Oklahoma·Phase 1·NCT01167816·9 enrolled

Myelodysplastic Syndromes1 trial

Azacytidine and Bortezomib in Treating Patients With Relapsed or Refractory Acute Myeloid Leukemia or Myelodysplastic Syndromes

Completed·OOhio State University Comprehensive Cancer Center·Phase 1·NCT00624936·23 enrolled

Trial1 trial

Blinded Cross-Over Bioequivalence (BE) Trial of Luitpold Azacitidine vs Vidaza

Completed·AAmerican Regent, Inc.·Phase 1·NCT01290302·38 enrolled

Sources

References

[1]
ClinicalTrials.gov — 9 trial records for Vidaza. U.S. National Library of Medicine, National Institutes of Health.
[2]
ChEMBL — Vidaza compound record. European Bioinformatics Institute (EMBL-EBI).
[3]
Open Targets Platform — Drug–disease associations for Vidaza. EMBL-EBI & Wellcome Sanger Institute.
[4]
SEC EDGAR — Bristol-Myers Squibb company filings. U.S. Securities and Exchange Commission.

Details

Drug Info

Quick Facts

Modality: Small molecule[2]
Highest Phase: Phase 1[1]
Company: Bristol-Myers Squibb

Vidaza

Status by Indication[3][1]

Competitive Landscape

Trials by Indication[1]

Myelodysplastic Syndrome2 trials

Non-Small Cell Lung Cancer1 trial

Safety and Efficacy1 trial

Hematologic Malignancies1 trial

Acute Myeloid Leukemia1 trial

Pancreatic Cancer1 trial

Myelodysplastic Syndromes1 trial

Trial1 trial

References

Drug Info

Quick Facts

Related News